RU2017117562A3 - - Google Patents

Download PDF

Info

Publication number
RU2017117562A3
RU2017117562A3 RU2017117562A RU2017117562A RU2017117562A3 RU 2017117562 A3 RU2017117562 A3 RU 2017117562A3 RU 2017117562 A RU2017117562 A RU 2017117562A RU 2017117562 A RU2017117562 A RU 2017117562A RU 2017117562 A3 RU2017117562 A3 RU 2017117562A3
Authority
RU
Russia
Application number
RU2017117562A
Other languages
Russian (ru)
Other versions
RU2017117562A (ru
RU2688677C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017117562A3 publication Critical patent/RU2017117562A3/ru
Publication of RU2017117562A publication Critical patent/RU2017117562A/ru
Application granted granted Critical
Publication of RU2688677C2 publication Critical patent/RU2688677C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
RU2017117562A 2014-10-24 2015-03-19 Лекарственные средства на основе лантионинсинтетаза с-подобного белка RU2688677C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462068322P 2014-10-24 2014-10-24
US62/068,322 2014-10-24
US201562101164P 2015-01-08 2015-01-08
US62/101,164 2015-01-08
PCT/US2015/021417 WO2016064445A1 (en) 2014-10-24 2015-03-19 Lanthionine synthetase c-like 2-based therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019110152A Division RU2741576C2 (ru) 2014-10-24 2015-03-19 Лекарственные средства на основе лантионинсинтетаза c-подобного белка 2

Publications (3)

Publication Number Publication Date
RU2017117562A3 true RU2017117562A3 (cg-RX-API-DMAC7.html) 2018-11-26
RU2017117562A RU2017117562A (ru) 2018-11-26
RU2688677C2 RU2688677C2 (ru) 2019-05-22

Family

ID=52811239

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2017117562A RU2688677C2 (ru) 2014-10-24 2015-03-19 Лекарственные средства на основе лантионинсинтетаза с-подобного белка
RU2019110152A RU2741576C2 (ru) 2014-10-24 2015-03-19 Лекарственные средства на основе лантионинсинтетаза c-подобного белка 2
RU2020133839A RU2768888C1 (ru) 2014-10-24 2020-10-15 Лекарственные средства на основе лантионинсинтетаза c-подобного белка 2

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2019110152A RU2741576C2 (ru) 2014-10-24 2015-03-19 Лекарственные средства на основе лантионинсинтетаза c-подобного белка 2
RU2020133839A RU2768888C1 (ru) 2014-10-24 2020-10-15 Лекарственные средства на основе лантионинсинтетаза c-подобного белка 2

Country Status (21)

Country Link
US (9) US9556146B2 (cg-RX-API-DMAC7.html)
EP (2) EP3757099B1 (cg-RX-API-DMAC7.html)
JP (3) JP6499306B2 (cg-RX-API-DMAC7.html)
KR (3) KR102026342B1 (cg-RX-API-DMAC7.html)
CN (2) CN111592508A (cg-RX-API-DMAC7.html)
AU (3) AU2015337091B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017008416B1 (cg-RX-API-DMAC7.html)
CA (1) CA2965472C (cg-RX-API-DMAC7.html)
DK (1) DK3209655T3 (cg-RX-API-DMAC7.html)
ES (1) ES2822987T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201416T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051299T2 (cg-RX-API-DMAC7.html)
IL (2) IL252630B (cg-RX-API-DMAC7.html)
LT (1) LT3209655T (cg-RX-API-DMAC7.html)
NZ (1) NZ732213A (cg-RX-API-DMAC7.html)
PL (1) PL3209655T3 (cg-RX-API-DMAC7.html)
PT (1) PT3209655T (cg-RX-API-DMAC7.html)
RS (1) RS61013B1 (cg-RX-API-DMAC7.html)
RU (3) RU2688677C2 (cg-RX-API-DMAC7.html)
SI (1) SI3209655T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016064445A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3209655T1 (sl) 2014-10-24 2020-11-30 Landos Biopharma, Inc. Terapevtiki na osnovi C-podobne lantionin sintetaze 2
US11529354B2 (en) 2017-09-05 2022-12-20 President And Fellows Of Harvard College Methods and compositions for the treatment of tuberculosis
WO2019099426A1 (en) * 2017-11-17 2019-05-23 Icahn School Of Medicine At Mount Sinai Influenza virus inhibitor targeting nucleoprotein
CA3083442A1 (en) 2017-11-30 2019-06-06 Landos Biopharma, Inc. Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
AU2020407645B2 (en) * 2019-12-20 2022-10-06 Nimmune Biopharma, Inc. Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
WO2022057928A1 (zh) 2020-09-18 2022-03-24 上海医药集团股份有限公司 一种羰基杂环类化合物及其应用
WO2022057932A1 (zh) * 2020-09-18 2022-03-24 上海医药集团股份有限公司 一种羰基杂环类化合物及其应用
AU2021365128A1 (en) 2020-10-22 2023-06-01 Nimmune Biopharma, Inc. Lancl ligands
US11492342B2 (en) 2020-11-03 2022-11-08 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)
EP4225315A2 (en) * 2020-11-19 2023-08-16 Nimmune Biopharma, Inc. Compounds, compositions, and methods for treating inflammatory or immune-mediated conditions of surface tissues
WO2022127774A1 (zh) * 2020-12-15 2022-06-23 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
CN113908256B (zh) * 2021-11-26 2023-05-26 中国农业科学院兰州兽医研究所 Lancl1蛋白在制备抗病毒药物中的应用
WO2024155555A1 (en) * 2023-01-16 2024-07-25 Nimml Institute Neuroprotective compounds for therapeutic use

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282643A3 (en) 1986-11-22 1990-08-22 The Green Cross Corporation Use of pharmaceutical compositions comprising cyclohexane derivatives in the treatment or prevention of peptic ulcers
FI972673L (fi) * 1994-12-23 1997-08-19 Smithkline Beecham Corp 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdisteitä
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
DE69738907D1 (de) * 1996-10-11 2008-09-25 Kowa Co Neue diamidverbindungen und medikamente die diese enthalten
KR20010033528A (ko) * 1997-12-24 2001-04-25 헨리 필리 파르, 올리비에 보우언 골다공증의 치료를 위한 ａ.ｏ.에 유용한 인돌 유도체
EP1052992A1 (en) 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
JP2001247550A (ja) * 1999-12-27 2001-09-11 Japan Tobacco Inc 縮合環化合物及びその医薬用途
WO2001064666A1 (en) * 2000-03-02 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
RU2297413C2 (ru) 2000-09-15 2007-04-20 Анормед, Инк. Гетероциклические соединения, моделирующие активность хемокинового рецептора, их применение и содержащая их фармацевтическая композиция
HUP0302960A3 (en) 2000-09-15 2007-03-28 Anormed Inc Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
JPWO2005037269A1 (ja) 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
JPWO2005082905A1 (ja) * 2004-02-26 2007-08-02 協和醗酵工業株式会社 二環性複素環化合物
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
EP1814393A4 (en) 2004-11-04 2010-02-03 Med College Georgia Res Inst TOLEROGENIC VACCINATE AND METHOD
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
WO2006080821A1 (en) 2005-01-28 2006-08-03 Daewoong Pharmaceutical Co., Ltd. Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
CN100434419C (zh) 2005-06-03 2008-11-19 中国人民解放军军事医学科学院毒物药物研究所 单环多取代饱和环已酮类化合物及其制备方法和用途
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
US7956082B2 (en) 2005-07-22 2011-06-07 Shionogi & Co., Ltd Indole derivative having PGD2 receptor antagonist activity
EP1911759A4 (en) 2005-07-22 2010-07-21 Shionogi & Co AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR
PL1910384T3 (pl) 2005-08-04 2013-03-29 Sirtris Pharmaceuticals Inc Pochodne imidazo[2,1-b]tiazolu jako związki modulujące sirtuinę
EP1932839A4 (en) 2005-09-06 2014-09-10 Shionogi & Co INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
UY29825A1 (es) 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US8367727B2 (en) 2006-02-08 2013-02-05 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
US7741367B2 (en) 2006-02-08 2010-06-22 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
JP2008056615A (ja) 2006-08-31 2008-03-13 Fujifilm Corp ビニルエチニルアリールカルボン酸類、その製造方法及びそれを用いた熱架橋性化合物の製造方法
JP2010510254A (ja) 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ， インコーポレイテッド アルツハイマー病および関連の神経変性疾患のための併用処置
JP2010513519A (ja) 2006-12-22 2010-04-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼインヒビター活性を有するある種のピラゾリン誘導体
WO2008092006A2 (en) 2007-01-24 2008-07-31 Cernofina, Llc Antimicrobial compositions
MY146643A (en) 2007-07-30 2012-09-14 Dae Woong Pharma Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
WO2009067621A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
CN102089279A (zh) 2007-11-21 2011-06-08 解码遗传Ehf公司 用于治疗炎症的联芳基pde4抑制剂
WO2010050461A1 (ja) 2008-10-27 2010-05-06 田辺三菱製薬株式会社 新規アミド誘導体およびその医薬としての用途
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
CA2647900C (en) 2008-12-23 2017-05-16 National Research Council Of Canada Inhibitors of a 9-cis-epoxycarotenoid dioxygenase
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
WO2010121046A1 (en) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
US9062564B2 (en) * 2009-07-31 2015-06-23 General Electric Company Solvent based slurry compositions for making environmental barrier coatings and environmental barrier coatings comprising the same
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
DE102009057167A1 (de) 2009-12-05 2011-06-09 Merck Patent Gmbh Elektronische Vorrichtung enthaltend Metallkomplexe
JP2011246461A (ja) 2010-04-27 2011-12-08 Mitsubishi Tanabe Pharma Corp 新規アミド誘導体を含有する医薬組成物
US9101573B2 (en) * 2010-05-04 2015-08-11 Virginia Tech Intellectual Properties, Inc. Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders
US8993624B2 (en) 2010-05-26 2015-03-31 Virginia Tech Intellectual Properties, Inc. Method of preventing and treating inflammatory diseases and disorders with abscisic acid
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
AU2011268375B2 (en) 2010-06-17 2015-02-05 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
KR20120035285A (ko) 2010-10-05 2012-04-16 에스케이이노베이션 주식회사 셀룰로오스아세테이트 필름
EP2797889A4 (en) 2011-12-30 2015-06-03 Centaurus Biopharma Co Ltd NOVEL ARYL ALKEN DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS
CN103709115A (zh) 2012-10-09 2014-04-09 山东亨利医药科技有限责任公司 截短侧耳素类抗生素衍生物
CN105228700A (zh) 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
JP6150701B2 (ja) 2013-09-30 2017-06-21 キヤノン株式会社 電子写真感光体、プロセスカートリッジおよび電子写真装置
SI3209655T1 (sl) * 2014-10-24 2020-11-30 Landos Biopharma, Inc. Terapevtiki na osnovi C-podobne lantionin sintetaze 2

Also Published As

Publication number Publication date
US10682349B2 (en) 2020-06-16
CN111592508A (zh) 2020-08-28
US10849895B2 (en) 2020-12-01
AU2015337091A1 (en) 2017-06-15
IL252630A0 (en) 2017-07-31
JP6499306B2 (ja) 2019-04-10
RU2019110152A3 (cg-RX-API-DMAC7.html) 2019-09-26
US20180055841A1 (en) 2018-03-01
WO2016064445A1 (en) 2016-04-28
RU2768888C1 (ru) 2022-03-25
CN107108573A (zh) 2017-08-29
RS61013B1 (sr) 2020-11-30
CN107108573B (zh) 2020-06-16
JP6806829B2 (ja) 2021-01-06
NZ732213A (en) 2019-02-22
LT3209655T (lt) 2021-01-11
US20160115153A1 (en) 2016-04-28
US12502388B2 (en) 2025-12-23
US11571419B2 (en) 2023-02-07
DK3209655T3 (da) 2020-09-28
US20170119762A1 (en) 2017-05-04
PL3209655T3 (pl) 2020-12-28
EP3757099A1 (en) 2020-12-30
HUE051299T2 (hu) 2021-03-01
PT3209655T (pt) 2020-11-13
IL275155A (en) 2020-07-30
ES2822987T3 (es) 2021-05-05
US20180289703A1 (en) 2018-10-11
RU2019110152A (ru) 2019-05-21
NZ746737A (en) 2021-06-25
US10493072B2 (en) 2019-12-03
RU2017117562A (ru) 2018-11-26
KR20170084115A (ko) 2017-07-19
US20230142910A1 (en) 2023-05-11
BR112017008416A2 (pt) 2018-01-23
US10201538B2 (en) 2019-02-12
EP3209655B1 (en) 2020-07-15
AU2021201405B2 (en) 2023-09-14
EP3209655A1 (en) 2017-08-30
RU2688677C2 (ru) 2019-05-22
US20210046070A1 (en) 2021-02-18
US20200261447A1 (en) 2020-08-20
US10028950B2 (en) 2018-07-24
BR112017008416B1 (pt) 2023-05-09
AU2015337091B2 (en) 2018-11-22
SI3209655T1 (sl) 2020-11-30
US20200046694A1 (en) 2020-02-13
JP2021073170A (ja) 2021-05-13
IL252630B (en) 2020-06-30
KR20190112181A (ko) 2019-10-02
JP2019142873A (ja) 2019-08-29
US9556146B2 (en) 2017-01-31
CA2965472A1 (en) 2016-04-28
JP2017533263A (ja) 2017-11-09
KR20200087273A (ko) 2020-07-20
AU2019201231A1 (en) 2019-03-21
US20190125744A1 (en) 2019-05-02
US9839635B2 (en) 2017-12-12
EP3757099B1 (en) 2022-06-01
CA2965472C (en) 2021-08-24
HRP20201416T1 (hr) 2020-12-11
IL275155B (en) 2021-04-29
KR102134171B1 (ko) 2020-07-15
KR102026342B1 (ko) 2019-09-27
AU2021201405A1 (en) 2021-03-25
RU2741576C2 (ru) 2021-01-27

Similar Documents

Publication Publication Date Title
BR112016018076A2 (cg-RX-API-DMAC7.html)
BR112016016195A2 (cg-RX-API-DMAC7.html)
BR112016013563A2 (cg-RX-API-DMAC7.html)
BR112016015813A2 (cg-RX-API-DMAC7.html)
BR112016016951A2 (cg-RX-API-DMAC7.html)
BR112016018238A2 (cg-RX-API-DMAC7.html)
BR112016017303A2 (cg-RX-API-DMAC7.html)
BR112016016088A2 (cg-RX-API-DMAC7.html)
BR112016016094A2 (cg-RX-API-DMAC7.html)
BR112016016741A2 (cg-RX-API-DMAC7.html)
BR112016018369A2 (cg-RX-API-DMAC7.html)
BR112016012874A2 (cg-RX-API-DMAC7.html)
BR112016017657A2 (cg-RX-API-DMAC7.html)
BR112016016451A2 (cg-RX-API-DMAC7.html)
BR112016017137A2 (cg-RX-API-DMAC7.html)
BR112016011585A2 (cg-RX-API-DMAC7.html)
BR112016018575A2 (cg-RX-API-DMAC7.html)
BR112016018705A2 (cg-RX-API-DMAC7.html)
BR112016015779A2 (cg-RX-API-DMAC7.html)
BR112016016992A2 (cg-RX-API-DMAC7.html)
BR112016016268A2 (cg-RX-API-DMAC7.html)
BR112016016944A2 (cg-RX-API-DMAC7.html)
BR112016017216A2 (cg-RX-API-DMAC7.html)
BR112016016537A2 (cg-RX-API-DMAC7.html)
BR112016017679A2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant